Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 04:35PM GMT
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst

All right. Perfect. Welcome, everyone, to the Credit Suisse Annual Healthcare Conference. I'm Tiago Fauth, I'm a lead biotech analyst at CS. We're joined today by BioMarin. We have Jeff, Chief Commercial Officer; and Brian, Chief Financial Officer for a fireside chat today. We'll try to leave about 5 minutes towards the end for Q&A if there are any questions from the audience.

Questions and Answers:

Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst

But I guess to kick it off, let's start big picture as BioMarin is kind of evolving towards larger indications in VOXZOGO ultra-rare. What does that mean in terms of the business strategy, operating leverage investments in the early stage pipeline, and we'll get into some more specifics following that.

Brian R. Mueller - BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO

Yes, great. Thanks so
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot